August 6th, 2009
The US FDA has officially announced their approval to market Onsolis, an advanced treatment used for the management of breakthrough pain, for cancer patients over the age of eighteen, who already receive and have built a tolerance to opiod therapy for unrelenting cancer pain.
Onsolis is the first product on the market to use the company’s BEMA technology (BioErodible MucoAdhesive). This drug delivery technology is composed of a small dissolvable polymer film which is applied to the patient’s inner lining of the cheek.
Onsolis is set to be made available in the fourth quarter of 2009, and will later be commercialized in the US by Meda Pharmaceuticals